Coagulation - Clinical Assessment and Disorders

Medical Assessment of Coagulation Introduction Coagulation disorders affect the body's ability to form and dissolve blood clots. Understanding how to assess these disorders requires knowing what laboratory tests measure, how to interpret their results, and which disorders they indicate. This guide will help you understand the practical application of coagulation testing and how to connect test results to clinical conditions. Understanding the Coagulation Pathways Before diving into tests, it's essential to understand that blood coagulation occurs through three interrelated pathways: the intrinsic pathway, extrinsic pathway, and common pathway. These pathways work together to transform fibrinogen into stable fibrin clots. The intrinsic pathway is initiated by contact with a damaged blood vessel surface and involves factors XII, XI, IX, and VIII. The extrinsic pathway is triggered by tissue damage and involves tissue factor (TF) and factor VII. Both pathways converge into the common pathway, which involves factors X, V, II (prothrombin), and I (fibrinogen), ultimately producing a cross-linked fibrin clot. Understanding which factors belong to which pathway is critical because coagulation tests are designed to detect problems in specific pathways. Common Laboratory Tests for Coagulation Prothrombin Time (PT) and International Normalized Ratio (INR) The prothrombin time (PT) measures how long it takes blood to clot when tissue factor is added to the patient's plasma. This test specifically assesses the extrinsic pathway and common pathway. A normal result is typically 11–13.5 seconds, but results vary by laboratory. PT results are standardized using the International Normalized Ratio (INR): $$ \text{INR} = \left( \frac{\text{Patient PT}}{\text{Mean Normal PT}} \right)^{\text{ISI}} $$ where ISI is the International Sensitivity Index (a standardization factor). The INR converts PT results into a standardized value so that results are comparable across different laboratories and reagents. This is particularly important for monitoring patients on warfarin, an oral anticoagulant. A prolonged PT/INR indicates deficiency of factors II, V, VII, or X. It may also result from oral anticoagulant therapy (warfarin) or liver disease, which decreases synthesis of most clotting factors. Activated Partial Thromboplastin Time (aPTT) The activated partial thromboplastin time (aPTT) measures how long it takes blood to clot when certain substances are added to activate the intrinsic pathway. Normal aPTT is typically 25–35 seconds. aPTT specifically assesses the intrinsic pathway and common pathway. It will be prolonged if there is a deficiency of factors VIII, IX, XI, or XII, or if heparin (an anticoagulant) is present in the blood. Thrombin Clotting Time (TCT) and Fibrinogen Assays The thrombin clotting time (TCT) measures how long it takes fibrinogen to convert into fibrin when thrombin is added directly. It assesses the final step of coagulation. The Clauss fibrinogen assay quantifies the functional fibrinogen concentration, providing information about how much fibrinogen is present and whether it functions normally. Key point: Fibrinogen deficiency will prolong the PT, aPTT, TCT, and reptilase time simultaneously, because fibrinogen is part of the common pathway. Platelet Assessment Platelet count is a simple but critical test that assesses primary hemostasis (the initial stage of clotting involving platelets). Platelet function testing can assess whether platelets aggregate and adhere properly. Interpreting Coagulation Test Results One of the most important skills in coagulation assessment is pattern recognition. Different combinations of abnormal tests point to different problems. Prolonged aPTT with Normal PT This pattern suggests a deficiency in the intrinsic pathway because: The intrinsic pathway (measured by aPTT) is abnormal The extrinsic pathway (measured by PT) is normal The common pathway must be working (PT is normal) This indicates deficiency of factor VIII, IX, XI, or XII. For example, hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) present this way. Prolonged PT with Normal aPTT This pattern indicates a deficiency in the extrinsic pathway only, suggesting factor VII deficiency (which is rare). Prolonged Both PT and aPTT When both PT and aPTT are prolonged, the defect must be in the common pathway because: Both pathways converge in the common pathway A problem in the common pathway affects both tests This pattern indicates deficiency of factors II, V, X, or fibrinogen. Disseminated intravascular coagulation (DIC) presents this way because it consumes multiple clotting factors. Normal PT and aPTT with Abnormal Fibrinogen If both PT and aPTT are normal but fibrinogen is deficient or dysfunctional, suspect a fibrinogen disorder. Remember that fibrinogen deficiency prolongs PT, aPTT, and TCT. Specialized Testing Mixing Studies Mixing studies are used to distinguish between factor deficiencies and inhibitors. The patient's plasma is mixed with normal plasma: If the result corrects: The patient has a factor deficiency (the normal plasma provides the missing factor) If the result doesn't correct: The patient likely has an inhibitor (such as an antibody against a clotting factor), because adding normal plasma doesn't fix the problem Dilute Russell's Viper Venom Time (dRVVT) This specialized test detects lupus anticoagulant, an unusual type of inhibitor that paradoxically causes an unexpected prolonged aPTT despite being a hypercoagulable state (increasing clot formation risk, not bleeding risk). This is a tricky point: the test result suggests bleeding risk, but the patient actually has thrombotic risk. D-Dimer and Fibrin Degradation Products D-dimer is a breakdown product of cross-linked fibrin, released when fibrin clots are dissolved. Elevated D-dimer indicates active fibrinolysis (clot breakdown). D-dimer is used to screen for: Disseminated intravascular coagulation (DIC), where fibrinolysis is excessive Thrombotic activity D-dimer is sensitive but not specific; it's elevated in many conditions including pregnancy, infection, and trauma. Genetic Testing Genetic testing identifies inherited thrombophilias: Factor V Leiden mutation produces a version of factor V that resists inactivation by protein C, increasing thrombosis risk Prothrombin gene mutation (G20210A) increases prothrombin levels, increasing thrombosis risk <extrainfo> These genetic mutations are identified in patients with unexplained thrombosis or a strong family history of clotting. However, genetic testing details are less critical for most coagulation assessments. </extrainfo> Coagulation Disorders Platelet Disorders Platelet disorders affect primary hemostasis (the formation of the platelet plug, the first phase of clotting). Glanzmann's thrombasthenia is a rare bleeding disorder caused by defective glycoprotein IIb/IIIa, which is essential for platelet aggregation (platelets clumping together). Patients have normal platelet counts but severe bleeding because their platelets cannot stick to each other. Bernard–Soulier syndrome results from abnormalities in the glycoprotein Ib/IX/V complex, which allows platelets to adhere to von Willebrand factor and to exposed vessel walls. This causes both low platelet count and impaired platelet function. Von Willebrand disease involves deficiency or dysfunction of von Willebrand factor, a protein that acts as a bridge between platelets and vessel walls. This leads to impaired platelet adhesion and abnormal bleeding. It is the most common inherited bleeding disorder. Hemophilias: Coagulation Factor Deficiencies The hemophilias are inherited deficiencies of clotting factors. They present with prolonged aPTT and normal PT because they involve intrinsic pathway factors. Hemophilia A is the most common hemophilia, caused by factor VIII deficiency. It ranges from mild to severe depending on factor VIII levels. Severe hemophilia A causes spontaneous bleeding into joints and muscles. Hemophilia B (Christmas disease) is caused by factor IX deficiency. It presents identically to hemophilia A and is distinguished only by specific factor assays. Hemophilia C is caused by factor XI deficiency and usually results in mild bleeding, unlike hemophilias A and B. Thrombophilias: Inherited Hypercoagulable States Thrombophilias are conditions that increase clot formation risk. They are often discovered after a patient experiences unexplained thrombosis (blood clot formation). Factor V Leiden, the most common inherited thrombophilia, results from a genetic mutation that prevents inactivation of factor V by protein C. This allows factor V to remain active longer, promoting clot formation. Antithrombin deficiency reduces levels of antithrombin, a natural anticoagulant that inhibits thrombin and factor Xa. Without adequate antithrombin, these clotting factors remain active, increasing thrombosis risk. Protein S deficiency impairs the protein C anticoagulant pathway. Protein S acts as a cofactor for protein C, which inactivates factors V and VIII. Deficiency leads to a hypercoagulable state. Acquired Coagulation Disorders Liver disease significantly impairs coagulation because the liver synthesizes most clotting factors (factors I, II, V, VII, IX, X, XI, XII, and fibrinogen). Liver disease results in deficiency of multiple factors, causing both PT and aPTT prolongation and increased bleeding risk. Immune thrombocytopenic purpura (ITP) is an autoimmune condition where the body produces antibodies against platelets, destroying them. This causes thrombocytopenia (low platelet count) and bleeding risk despite normal coagulation factor levels. Disseminated intravascular coagulation (DIC) is a life-threatening condition where widespread clotting and fibrinolysis occur simultaneously. DIC consumes platelets and clotting factors, leading to both severe bleeding and thrombosis. Laboratory findings include: Prolonged PT and aPTT (factor consumption) Low platelet count (platelet consumption) Elevated D-dimer (active fibrinolysis) Low fibrinogen (consumption) Summary: Connecting Tests to Disorders Understanding coagulation assessment means recognizing patterns: Prolonged aPTT, normal PT → Intrinsic pathway problem (factors VIII, IX, XI, XII) → Think hemophilia Prolonged PT and aPTT → Common pathway problem (factors II, V, X, fibrinogen) → Think liver disease or DIC Normal coagulation tests, low platelets → Primary hemostasis problem → Think ITP or platelet disorder Unexpected isolated aPTT prolongation that doesn't correct on mixing study → Inhibitor (such as lupus anticoagulant) → Risk of thrombosis, not bleeding Normal tests, family history of clots → Inherited thrombophilia → Consider genetic testing This systematic approach allows you to use coagulation testing effectively to diagnose and monitor bleeding and clotting disorders.